Results 41 to 50 of about 19,808 (220)

Common ADRB2 Haplotypes Derived from 26 Polymorphic Sites Direct β2-Adrenergic Receptor Expression and Regulation Phenotypes [PDF]

open access: yes, 2012
Background: The β2-adrenergic receptor (β2AR) is expressed on numerous cell-types including airway smooth muscle cells and cardiomyocytes. Drugs (agonists or antagonists) acting at these receptors for treatment of asthma, chronic obstructive pulmonary ...
Hawkins, Gregory A.   +6 more
core   +1 more source

CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer [PDF]

open access: yes, 2019
Background: Molecular targeting remains to be a promising approach in oncology. Overexpression of G protein-coupled receptors (GPCRs) in human cancer is offering a powerful opportunity for tumor-selective imaging and treatment employing nuclear medicine.
Bandholtz, Sebastian   +12 more
core   +1 more source

New Insights in PRRT: Lessons From 2021

open access: yesFrontiers in Endocrinology, 2022
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has been used for over two decades for the treatment of well-differentiated neuroendocrine tumors (NETs), and the publication of the NETTER-1 trials has further ...
Giulia Puliani   +6 more
doaj   +1 more source

Cancer‐Associated Fibroblasts Functions as Multifunctional Architects of the Tumor Stroma and Represent Emerging Therapeutic Vulnerabilities

open access: yesAdvanced Science, EarlyView.
ABSTRACT Cancer‐associated fibroblasts (CAFs) are the predominant stromal components within the tumor microenvironment (TME), playing multifaceted roles in cancer progression through dynamic interactions with neoplastic and immune cells. Emerging evidence has revealed remarkable heterogeneity and plasticity of CAFs, which originate from diverse ...
Rujiao Liu   +4 more
wiley   +1 more source

Serotonin reuptake inhibitors and cardiovascular disease [PDF]

open access: yes, 2005
Selective serotonin re-uptake inhibiting drugs (SSRIs) are widely used for endogenous depression. In addition to depleting the nerve terminals of serotonin they also lower blood platelet serotonin levels.
Belcher, P.R.   +2 more
core   +1 more source

Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies

open access: yesMolecules, 2022
Radioligand therapy (RLT) is an emergent drug class for cancer treatment. The dose administered to cancer patients is constrained by the radiation exposure to normal tissues to maintain an appropriate therapeutic index.
Joseph Lau   +4 more
doaj   +1 more source

DSG2+ Cancer Stem Cells Co‐Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non‐Small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
Cancer stem cells (CSCs) in non‐small cell lung cancer display pronounced plasticity and spatial heterogeneity. By integrating single‐cell and spatial transcriptomics, this study defines a DSG2‐associated CSC program and reveals a tumor‐margin niche formed with FAP+ myofibroblasts.
Guangyu Fan   +8 more
wiley   +1 more source

Circulating Tumour Necrosis Factor is highly correlated with brainstem serotonin transporter availability in humans [PDF]

open access: yes, 2016
Preclinical studies demonstrate that pro-inflammatory cytokines increase serotonin transporter availability and function, leading to depressive symptoms in rodent models.
Burden, A. David   +10 more
core   +1 more source

Recent Advances in Radioligand Therapy

open access: yeshealthbook TIMES. Oncology Hematology
Radioligand therapy (RLT) is a targeted molecular approach that couples the specificity of receptor-mediated binding with the cytotoxic effects of radionuclide emission to achieve selective tumor irradiation while limiting damage to healthy tissues. This
Irene A. Burger
doaj   +1 more source

Design and In-silico Study of ¹³¹Iodium Radiolabeled of Thiourea derivatives for Breast Cancer Treatment

open access: yesJurnal Kimia Sains dan Aplikasi
Breast cancer is a serious challenge in both developed and developing countries, with current therapies still limited and potentially producing adverse side effects.
Miqdad Nurabdullah Al Anshari   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy